Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.

The present study, carried out in 16 parkinsonian patients, indicates that L-prolyl-L-leucyl-glycine amide possesses some antiparkinsonian activity and that, if used with levodopa, it can reduce some of the drug-induced dyskinesias. These preliminary observations should be submitted to a controlled trial in a large number of patients before therapeutic applications are claimed.
AuthorsA J Kastin, A Barbeau
JournalCanadian Medical Association journal (Can Med Assoc J) Vol. 107 Issue 11 Pg. 1079-81 (Dec 9 1972) ISSN: 0008-4409 [Print] CANADA
PMID4640811 (Publication Type: Journal Article)
Chemical References
  • Amides
  • Antiparkinson Agents
  • Peptides
  • Dihydroxyphenylalanine
  • Proline
  • Leucine
  • Glycine
  • Administration, Oral
  • Aged
  • Amides (therapeutic use)
  • Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
  • Dihydroxyphenylalanine (adverse effects, therapeutic use)
  • Female
  • Glycine
  • Humans
  • Injections, Intravenous
  • Leucine
  • Male
  • Middle Aged
  • Movement Disorders (chemically induced)
  • Parkinson Disease (drug therapy)
  • Peptides (administration & dosage, adverse effects, therapeutic use)
  • Proline

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: